Fatigue, tumor asscociated
Conditions
Interventions
Group 1: Patients with histologically or cytologically confirmed various tumor entities for whom therapy with Epirubicin LIV Pharma is indicated according to the enclosed SmPC.
The special warnings an
Sponsors
LIV Pharma GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Histologically or cytologically confirmed tumor diseases of the female breast or ovaries for which Epirubicin LIV Pharma is approved as a drug according to the specialist information - Age: older than 18 years - Epirubicin LIV Pharma is used in therapy. - A hand-dated and signed consent is available. - The therapy was selected independently of a possible study inclusion.
Exclusion criteria
Exclusion criteria: - Contraindications to the use of Epirubicin LIV Pharma according to the SmPC. - The current therapy was started more than 12 weeks ago. - The patient is participating in a clinical trial at the same time. - Pregnancy is present or the patient is breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy and Tolerability routine practice. Observational, non-interventional study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects which were not observed so far. | — |
Countries
Germany
Contacts
Public ContactBurkard Heckelbacher
Datafaber GbR
Outcome results
None listed